Additional Hetero Ring Patents (Class 514/422)
  • Patent number: 11883380
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 30, 2024
    Assignee: HUYABIO INTERNATIONAL, LLC
    Inventors: Suzanne J. Romano, Gary T. Elliott
  • Patent number: 11833146
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: December 5, 2023
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • Patent number: 11739082
    Abstract: The present invention relates to novel thiophene compounds of general Formula I, and their stereoisomers (diastereoisomers, enantiomers), pure or mixed, racemic mixtures, geometrical isomers, tautomers, pharmaceutically acceptable salts, hydrates, solvates, solid forms and mixtures thereof along with process for their preparation. The present invention discloses compounds that are useful in the treatment and prevention of autoimmune diseases.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 29, 2023
    Assignee: Ahammune Biosciences Private Limited
    Inventors: Kashinath Komirishetty, Mahesh Kumar Verma, Parul Ganju, Sudhanand Prasad
  • Patent number: 11707475
    Abstract: A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound. A method of treating multiple disease causes, by administering a glycocalyx restoring and maintaining compound to an individual, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage. A method of treating cardiovascular disease. A method of restoring the glycocalyx. A method of reversing inflammation. A method of reversing oxidative damage. A method of treating any disease involving a membrane that has a glycocalyx. A method of treating multiple disease causes. A method of restoring the structural and functional integrity of receptors in the glycocalyx. A method of restoring the glycocalyx and receptors therein and potentiating drug response. A composition for treating disease including the glycocalyx restoring and maintaining compound and an antibody.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: July 25, 2023
    Assignee: Arterez, INC.
    Inventor: Josefino B. Tunac
  • Patent number: 11638698
    Abstract: A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: May 2, 2023
    Assignee: Zeenar Enterprises Pty Ltd
    Inventors: Gregory Yu Foo Szto, Tomer Madmon, David Kannar
  • Patent number: 11591284
    Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 28, 2023
    Assignee: NMD PHARMA A/S
    Inventors: Lars J. S. Knutsen, Thomas Holm Pedersen, Claus Elsborg Olesen, Marc A. Labelle, Paul Brian Little, Martin E. Cooper, Neerja Saraswat, Dastagiri Dudekula, Rafiq A. Taj
  • Patent number: 11564909
    Abstract: Liquid oral pilocarpine formulations are described herein. Methods of using the liquid oral pilocarpine formulations are also provided.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: January 31, 2023
    Assignee: ROMEG Therapeutics LLC
    Inventors: Indu Muni, Naomi Vishnupad
  • Patent number: 11491137
    Abstract: Provided herein are methods of improving kidney function in a subject in need thereof.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: November 8, 2022
    Assignee: Chinook Therapeutics, Inc.
    Inventors: Philip Thomas Frohlich, Andrew James King, Chidambaram Ramachandran, Sarah Beth Noonberg
  • Patent number: 11452709
    Abstract: The invention provides novel compositions and methods for the treatment of Radiation-Induced Bystander Effects (RIBE), resulting from radiation exposure. In one preferred embodiment the inventions includes novel therapeutic agents, including but not limited to quercetin and quercetin analogs, as well as E64, CA074, CA074Me, that interfere with the activity of Cathepsin B.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 27, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, TSINGHUA UNIVERSITY, CHANG GUNG UNIVERSITY
    Inventors: Ding Xue, Yu Peng, Man Zhang, Lingjun Zheng, Qian Liang, Hanzeng Li, Jau-Song Yu, Jeng-Ting Chen
  • Patent number: 11345690
    Abstract: The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R1, R4, R5, R6, and L1 are as defined herein. Compounds of formula (IA) have been found useful as EP4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 31, 2022
    Assignee: Cayman Chemical Company, Inc.
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo
  • Patent number: 11180486
    Abstract: The present invention discloses novel indolylkojyl compounds of formula 1 The invention also provides a one pot, green chemistry method for preparation of indolylkojyl compounds. The compounds of the present invention are selectively toxic towards human breast cancer cells and inhibit tumor growth as well as lung metastasis. The compounds also potentiate the effect of anticancer drugs.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: November 23, 2021
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Debaraj Mukherjee, Anindya Goswami, Deepak Sharma, Debasis Nayak, Shreyans Kumar Jain
  • Patent number: 11160789
    Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: November 2, 2021
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
  • Patent number: 11124479
    Abstract: The invention relates to compounds and pharmaceutical compositions capable of treating amyloid diseases and other diseases characterized by oligomerization and/or fibrillation of amyloidogenic peptides such as islet amyloid polypeptide (IAPP).
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: September 21, 2021
    Assignee: NEW YORK UNIVERSITY
    Inventors: Andrew D. Hamilton, Sunil Kumar
  • Patent number: 10973801
    Abstract: The present disclosure is directed to methods of using a capsid assembly inhibitor for the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Koen Vandyck, Oliver Lenz, Claire Elisabeth Balmain, Jan Snoeys, Joris Jozef Vandenbossche, Dominique Josiane W. Verstraete, Jeysen Zivan Yogaratnam, Maria Jansens, Frederic Van Dycke
  • Patent number: 10888544
    Abstract: Methods for treating Gaucher disease in patients with renal or hepatic impairment.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 12, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Jing Li, M. Judith Peterschmitt, Vanaja Kanamaluru, Jun Chen, Sebastiaan J. M. Gaemers, Dan Rudin
  • Patent number: 10752616
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 25, 2020
    Assignee: King's College London
    Inventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
  • Patent number: 10688079
    Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 23, 2020
    Assignee: Piramal Enterprises Limited
    Inventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
  • Patent number: 10662153
    Abstract: Thin molecules, compounds producible by cleaving bilirubin at its methylene site in the center of the molecule, methods of making the same, and methods of using the same, are described.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 26, 2020
    Assignee: The University of Toledo
    Inventors: Terry D. Hinds, Jr., David E. Stec, Christopher J. Trabbic
  • Patent number: 10550225
    Abstract: [Problem] To provide a gel which can be produced in a short time, has controlled properties such as modulus and expansion pressure, and has a low polymer concentration. [Solution] A process for producing a polymer gel in which gel-precursor clusters have been crosslinked with one another to form a three-dimensional network structure, characterized by comprising a) a step in which monomer or polymer units that are present in a concentration less than a critical gelation concentration are crosslinked to form the gel-precursor clusters, the gel-precursor clusters having a storage modulus G? and a loss modulus G? which satisfy the relationship G?<G?, and b) a step in which the gel-precursor clusters are crosslinked with one another by a crosslinking agent to obtain a gel having a three-dimensional network structure.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: February 4, 2020
    Assignee: The University of Tokyo
    Inventors: Takamasa Sakai, Yuichi Tei
  • Patent number: 10500188
    Abstract: The present invention discloses use of a polyenylpyrrole derivative in preparation of an anti-oral cancer drugs. The polyenylpyrrole derivative synthesized by polyvinylpyrrole, auxarconjugatin A and 12E-isorumbrin inhibits the cell proliferation, migration, tumor sphere formation abilities and xenograft tumorigenicity of oral cancer cells.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: December 10, 2019
    Assignee: Tzu Chi University
    Inventors: Jeng-Woei Lee, Chia-Chen Lau, Kuo-Feng Hua, Yulin Lam
  • Patent number: 10441574
    Abstract: The present invention generally relates to a method of treating or preventing an endoplasmic reticulum stress disorder in subjects, such as a method of treating or preventing Wolfram syndrome.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: October 15, 2019
    Assignee: Washington University
    Inventors: Fumihiko Urano, Simin Lu
  • Patent number: 10413543
    Abstract: A stable multi-particulate pharmaceutical composition comprising pellets, the pellets comprising a mixture of rosuvastatin or its pharmaceutically acceptable salts as a sole active ingredient, one or more osmotic release modifiers and one or more stabilizers.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 17, 2019
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadikari, Yashoraj Zala, Ashwini Gadkari
  • Patent number: 10413542
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 17, 2019
    Assignees: Buck Institute for Research on Aging, Unity Biotechnology, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • Patent number: 10385044
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RARP?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 20, 2019
    Assignee: King's College London
    Inventors: Alan David Borthwick, Mark Trevor Mills, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barret Kalindjian
  • Patent number: 10385042
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 20, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 10385017
    Abstract: The present invention relates to compositions comprising saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight, and dimer compound of Formula (IV) present in an amount relative to saroglitazar magnesium less than about 0.3% by weight by area percentage of HPLC. The present invention also related to the process for the preparation thereof and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 20, 2019
    Assignee: Cadila Healthcare Limited
    Inventors: Sanjay Jagdish Desai, Ramesh Chandra Singh, Daya Ram Pal, Dharmendra Arvindbhai Darji
  • Patent number: 10369145
    Abstract: Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 6, 2019
    Assignee: DISCOVERYBIOMED, INC.
    Inventors: Erik Schwiebert, John Streiff, John Dixon, Hongwu Gao, Joseph P. Ritchie, Eric C. Seales, Deborah Mai
  • Patent number: 10328051
    Abstract: A pharmaceutical compositions including proline or proline derivatives is provided. A method for the treatment of dementia, Alzheimer's and neurodegenerative diseases with the compositions is also provided.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: June 25, 2019
    Inventor: Zoser B. Salama
  • Patent number: 10227312
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 12, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Bing Wang
  • Patent number: 10227323
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: March 12, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing Wang, Daniel Chu, Alexander James Bridges
  • Patent number: 10188606
    Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Xifeng Liu, Michael J. Yaszemski, Lichun Lu
  • Patent number: 10125097
    Abstract: The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: November 13, 2018
    Assignees: UNIVERSITAT DE BARCELONA, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA), IPROTEOS S.L.
    Inventors: Ernest Giralt Lledó, Teresa Tarragó Clua, Roger Prades Cosano, Soledad Royo Gracia
  • Patent number: 10098869
    Abstract: The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: October 16, 2018
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
  • Patent number: 10086071
    Abstract: Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 2, 2018
    Assignee: Palo Alto Investors
    Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
  • Patent number: 10028918
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 24, 2018
    Assignees: Albert Einstein College of Medicine, Inc., La Jolla Bioengineering Institute
    Inventors: Parimala Nacharaju, Adam J. Friedman, Joel M. Friedman
  • Patent number: 9994542
    Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 12, 2018
    Assignee: Amazentis SA
    Inventors: Christopher Lawrence Rinsch, Rune Andreas Ringom
  • Patent number: 9988376
    Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: June 5, 2018
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Sebastien Andre Campos, John David Harling, Afjal Hussain Miah, Ian Edward David Smith
  • Patent number: 9981018
    Abstract: A method of promoting hair growth of a subject includes administering to follicle cells of the subject a therapeutically effective amount of a TLR2 agonist that promotes TLR2 activation and hair growth of the subject.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: May 29, 2018
    Assignee: The Cleveland Clinic Foundation
    Inventor: Tatiana Byzova
  • Patent number: 9956260
    Abstract: Provided herein are compositions and methods for the treatment of a patient having an HIV-1 infection and/or AIDS. More specifically this invention provides treatment of an HIV-1 infection and/or AIDS using small molecule compounds, such as inhibitors for the activation and/or activity of caspase-1. Inhibitors for the activation and/or activity of caspase-1 also prevent the cell death of CD4 T-cells in a population of CD4 T-cells comprising HIV-1 infected CD4 T-cells and uninfected CD4 T-cells, In addition, caspase-1 inhibitors inhibit inflammation, and pyroptosis.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 1, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Warner C. Greene, Gilad Doitsh, Orlando Zepeda, Nicole Galloway
  • Patent number: 9815824
    Abstract: Provided are compounds of Formula I; and pharmaceutically acceptable salts and solvates thereof. The present disclosure relates to novel compounds and to their use as agonists of the kappa opioid receptor. The disclosure also relates to methods for preparation of the compounds and to pharmaceutical compositions containing such compounds. Kappa opioid agonists that exhibit full agonist properties at the kappa opioid receptor have been widely shown to be efficacious in preclinical models of pain, particularly visceral pain.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: November 14, 2017
    Assignee: Nektar Therapeutics
    Inventors: Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
  • Patent number: 9783528
    Abstract: This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 10, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Patent number: 9701630
    Abstract: Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 11, 2017
    Assignees: Cayman Chemical Company, Inc., Myometrics, LLC
    Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Thomas Allen Owen, James Paul O'Malley
  • Patent number: 9693988
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: July 4, 2017
    Assignee: DOW PHARMACEUTICAL SCIENCES, INC.
    Inventors: Yunik Chang, Gordon J. Dow
  • Patent number: 9671688
    Abstract: Disclosed are a monomer represented by the following Chemical Formula 1 for a hardmask composition, a hardmask composition including the monomer, and a method of forming patterns using the same. In the above Chemical Formula 1, A, A?, L, L?, X and n are the same as defined in the specification.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: June 6, 2017
    Assignee: Cheil Industries, Inc.
    Inventors: Seung-Wook Shin, Yun-Jun Kim, Hea-Jung Kim, Youn-Jin Cho, Yoo-Jeong Choi
  • Patent number: 9637476
    Abstract: The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: May 2, 2017
    Assignee: AbbVie Inc.
    Inventors: Yuchuan Gong, Geoff G. Zhang
  • Patent number: 9556155
    Abstract: The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 31, 2017
    Assignee: Genzyme Corporation
    Inventors: Hongmei Zhao, Nelson S. Yew, Seng H. Cheng, Canwen Jiang, Cynthia Marie Arbeeny
  • Patent number: 9532976
    Abstract: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 3, 2017
    Assignee: Genzyme Corporation
    Inventors: Seng H. Cheng, Nelson S. Yew, Ronald K. Scheule, Hongmei Zhao
  • Patent number: 9487510
    Abstract: The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (?) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 8, 2016
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Pradip Kumar Sasmal, Chintakunta Vamseekrishna, Vijay Potluri, Ashok Tehim, Yonghua Gai, Hang Zhang
  • Patent number: 9486443
    Abstract: The present invention is a method for treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: November 8, 2016
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh
  • Patent number: 9468210
    Abstract: Novel compositions and methods for the post-harvest treatment of crops are disclosed and described. In one example, a composition includes a fungicidally-active compound, an ether solvent, and a filler. In many embodiments, the composition is ready-to-fog.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 18, 2016
    Assignee: Syngenta Participations AG
    Inventors: Nagarajan Ramalingam, David Charles Ross, Matthew Robert Cottle, Eric Stephen Oshige, Gabriel Ian Oxby